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BACKGROUND Arterial aneurysms (An) are traditionally treated sur-
gically, but more and more by interventional procedures with a high
technical success rate, but some problems are not solved like pro-
tection of aneurysm rupture, endoleaks, stent thrombosis, collateral
branch thrombosis. We used a new concept of stent, the Multilayer
Flow Modulator (MFM*) to treat An. and try to avoid some drawbacks
encountered with endografts.
METHODS This MFM* is a 3 Dimensional braided tube made of several
interconnected layers without any covering. Our earliest in vitro
(theorical simulation), computerized Fluid dynamics, Molecular
Modelization and in vivo tests demonstrated that this MFM* reduces
the velocity in the aneurismal sac up to 90% by modifying the he-
modynamic conditions. A saccular aneurysm without collateral
branch will thrombose quickly. If a collateral branch is present the
ﬂow is directed towards this branch leading to shrinkage of the
aneurysm. Animal experiments show excellent results. Moreover, as
demonstrated in animal and human studies this MFM* preserves the
collateral branches allowing the possibility to cover any artery
without compromising the ﬂow (renal, digestive arteries, supra aortic
vessels.)
RESULTS 44 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8,
mesenteric:2, carotid: 2, Subclavian : 2, Caeliac trunk :1) were treated
with the MFM* (male:31, mean age 62þ/-8 y) (57 stents ⌀ 5 to 14 mm;
length 40 to 120 mm) were implanted to treat these aneurysms, by
femoral approach (43 cases), brachial approach (1 case), Technical
success in all patients. No complications. All An. thrombosed with
diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. 6 month to
36 month follow up will be presented and we will discuss the time
needed to achieve exclusion of the An. All the side branches remained
patent.
CONCLUSIONS A new concept of stent, the MFM* (without any
covering) is developed to treat An. It opens a new approach to treat
peripheral An. avoiding most of the complications encountered with
current endovascular techniques. The results obtained seem prom-
ising. A larger study is ongoing.
CATEGORIES ENDOVASCULAR: Peripheral Vascular Disease and
Intervention
KEYWORDS Aneurysm, Multilayer Flow Modulator, Stent
TCT-777
The Multilayer Flow Modulator Stent For The Treatment Of Thoraco
Abdominal And Abdominal Aortic Aneurysms. Moroccan Experience
Michel C. Henry,1 Amira Benjelloun,2 Isabelle Henry3
1cardiologie, BOFFERDANGE, Luxembourg; 2Clinique Coeur et
Vaisseaux, RABAT, Morocco; 3centre de cardiologie, ROUVROY, France
BACKGROUND Thoraco Abdominal Aortic Aneurysms (TAAA) and
Abdominal Aortic Aneurysms (AAA) are traditionally treated surgi-
cally, but more and more by interventional procedures (endografts,
fenestrated, branched grafts, chimney techniques). We used a new
concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
METHODS This selfexpandable M.F.M is a 3 D braided tube made of
several interconnected layers without any covering. We will explain
and demonstrate the key principles of the stent leading to thrombosis,
shrinkage of the A, eliminating the risk of rupture. The M.F.M pre-
serves the collateral branches allowing the possibility to cover any
artery without compromising the ﬂow (renal, digestive arteries, supra
aortic vessels.).Moreover it increases the ﬂow by 25% in Renal Ar-
teries and 23% in Supra Aortic branches
RESULTS 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated
with MFM in very high risk patients. 53 MFM implanted (1 to 5 per pt).
o Technical success: 100% o At 30 days: no neurological complication,
branch patency 100%, no death o During the follow up we had 3
deaths not device related. CT scan control performed at 1, 3, 6, 12, 18
months with calculation of A. Diameters and Volumes. o All collateral
branches remain patent and we observed a progressive thrombosis
and shrinkage of the aneurysmal sac depending on the size of the
collaterals. Some patients developed a thrombus after 1 month, someafter 6 months and some even after 18 months. o A signiﬁcant mean
diameter reduction was observed between baseline and 6 months:
15,99 mm reduction for the transversal diameter, 12,75 mm for the
antero posterior diameter in the TAAA group. o Overtime the ratio
thrombus volume / Total Volume is increasing and the ratio Residual
Flow Volume / Total Volume is decreasing. The problems of throm-
bosis, shrinkage and volume reduction of the aneurysmal sac will be
discussed. Long-term follow-up (5 years)will be presented The com-
plications rates with M.F.M appear lower in comparison with current
endovascular techniques, and with surgery.
CONCLUSIONS The M.F.M represents an alternative to current de-
vices to treat TAAA and AAA. It is a safe procedure with a low
complication rate. The ﬁrst results are promising. A larger study is
ongoing.
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BACKGROUND Renal Artery Aneurysms (RAAs) can be surgically
treated but due to high risk, endovascular procedures have been
proposed (coils, graft...). All these techniques have some drawbacks,
potential complications and contraindications. We propose a new
technique: the Multilayer Flow Modulator (MFM*), a self expandable.
METHODS This MFM* is a 3D braided tube made of several inter-
connected layers without any covering. Our earliest tests, in vitro
(theorical simulation computerized Fluid dynamics, Molecular
Modelization) & in vivo. demonstrate that this MFM* reduces the
velocity in the aneurismal sac up to 90% by modifying the hemody-
namic conditions.. A saccular aneurysm (A.) without collateral branch
will thrombose quickly. If a collateral branch is present the ﬂow is
directed towards this branch leading to shrinkage of the aneurysm. In
fusiform A. the ﬂow is laminated, the vortexes eliminated, eliminating
the risk of rupture. Animal experiments show excellent results.
Moreover, as demonstrated in animal and human studies this MFM
preserves the collateral branches and increases the ﬂow in them,
allowing the possibility to cover any artery without compromising the
ﬂow.
RESULTS 9 RAAs (right: 6, left: 3) in 9 pts (male: 4) mean age 58 y.
treated with MFM* 7 pts had atheromatous disease, 2 a ﬁbromuscular
dysplasia. One pt had a solitary kidney. All these pts had hyperten-
sion. 11 MFM*(⌀: 5 to 7 mm, length 30 to 60 mm) loaded in a 6 F sheath
implanted by femoral approach through 8 F guiding catheter. These
stents covered major renal branches without compromising the ﬂow.
Technical success: 100%. No complications. Immediately: important
reduction of the velocities inside the aneurismal sac. 6 to 36 month
follow up will be presented. All aneurysms thrombosed with diameter
reduction in some pts. The thrombosis could take several weeks
depending on the importance of collateral branches. All the side
branches remain patent.
CONCLUSIONS The MFM* is a new technique which seems promising
to treat RAAs. Collateral branches can be covered without compro-
mising the ﬂow and risk of renal infarction. It is a safe procedure with
a very low complications rate. Larger study is ongoing.
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BACKGROUND To evaluate the safety and efﬁciency of vertebral an-
gioplasty and stenting (VAS) in symptomatic patients.
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years (22-84) left 69. All pts had multivascular diseases: carotid
(CA):71, subclavian (SA): 33, coronary: 75. Atheromatous lesions: 116,
inﬂammatory: 4. Mean lesion length: 9,5 þ/- 2,9 mm. Mean % stenosis
83.6  7.8, mean arterial diameter : 4,8  0,6 mm (4-6). 112 lesions at
VO segment (ostium), 6 at V1 and 2 at V2 segments. Indications for
angioplasty: dizziness (110), bilateral weakness (12), visual changes
14), diplopia (12), drop attacks (24), TIA (15), ataxia (6). A protection
device (ﬁlter) used in 12 pts. 25 SA angioplasties performed at the
same time of VAS, 10 CA. All angioplasties performed by femoral
approach, 4 by brachial approaches after failure of femoral approach.
(2 successes).
RESULTS Technical success 118/120 (99%). 6 lesions treated by an-
gioplasty alone: 3 VO (ﬁrst 3 pts. 2 V1, 1 V2 lesion). 1 pt (inﬂammatory
disease) treated by cutting balloon alone. 111 lesions treated with
stents (direct stenting: 96). Peripheral balloon expandable stents
(n¼23), self expandable stents (n¼4 for 3 V1 and one V2 lesions). 88
coronary stents (20 DES). 1 pt developed a TIA during the procedure.
No neurological complications at 30 days Clinical success 112/114
(99%) Post-procedure arterial diameter: 4,60  0,8 mm (4-6). Mean
residual stenosis 2,5  3,9 %. In 12 pts treated with protection devices,
visible debris removed in 9 (6 Filterwire, 2 Fibernet) 1 Angioguard
with the same amount of debris as during Carotid Stenting) 9 pts (8%)
developed a symptomatic restenosis during the follow-up (mean:
33.4.29.9 months), 3 after PTA alone, 5 after PTA and stent (1 oc-
clusion treated medically, 7 stenoses successfully treated with PTA).
No restenosis after DES implantation at 1 year.
CONCLUSIONS VAS can be performed safely and effectively with a
high technical success rate, a low complication rate, a low restenosis
rate and a durable clinical success in patients with symptomatic VA
stenosis. Stents seem to improve immediate and long-term results.
The role of protection devices and D.E.S has to be discussed.
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BACKGROUND To review feasibility, safety and long-term results of
subclavian artery angioplasty.
METHODS 407 patients (males: 245, mean age: 66.1  12 y) underwent
percutaneous treatment for subclavian artery (SA) occlusive disease
(stenosis: 295, occlusion: 112). Left: 312, Right: 95, Innominate Artery:
28. Etiology: atheromatous: 397, others: 10 (Takayasu: 6) Mean %
stenosis 83.4 þ/- 7.8. Mean lesion length: 23.9 þ/- 8.7 mm Indications
for treatment were upper limb ischemia (ULI) (n¼177) Vertebrobasilar
insufﬁciency (VBI) (n¼157), associated VBI and ULI (n¼123), coronary
steal syndrome (n¼20) asymptomatic patients with severe coronary
disease (n¼73) 39 patients had associated Vertebral Artery stenosis, 81
carotid stenoses. 337 prevertebral lesion, 45 post vertebral, both 25.
Access: femoral (n¼287), brachial (n¼81), both (n¼39). “Pull through
technique”: 8 cases. An isolated balloon angioplasty was performed in
59 cases and 348 stents were implanted (balloon expandable: 276, self
expandable: 72).
RESULTS Technical success was obtained in 387 lesions (95 %)
100% for stenoses. Only 92 occlusions were recanalized (82 %). Four
periprocedural events occurred (1.2 %), 1 major (fatal stroke), 1
T.I.A., 2 arterial thromboses. During the follow-up (mean follow-up:
75.7 months  38.5), we had 40 restenoses (10 %). 13 occurred
following angioplasty alone (18.8 %) and 27 following angioplasty
and stent implantation (7.8 %) (P<0.01). 10 were treated by new
angioplasty alone, 30 by repeat stent implantation. Primary (PI) and
secondary (PII) patencies on an intention to treat basis at 10-year
follow-up were 80.2 % and 86.5 % respectively. In patients without
initial stent placement, the rates were 67.5 % and 75.5 % while in
those with stents, the rates rose to 91.5 % and 98.2 % (P < 0.01). PI
for all recanalized lesions were 85.8 %, 79.1 % without stent, 91.8 %
with stent (P < 0.04) and PII 92.8 %, 88.5 %, 98.1% respectively
(P < 0.02).CONCLUSIONS P.T.A. is currently the treatment of choice for sub-
clavian artery lesions. It is a safe and effective procedure associated
with low risks and good long-term results. Stents seem to limit the
restenosis rate and improve long-term results.
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BACKGROUND Decreased proximal aortic distensibility predicts all-
cause mortality and cardiovascular events. Radial aortic distensibility
is preserved after thoracic endovascular aortic repair (TEVAR), but its
impact on longitudinal aortic distensibility (LAD) has not yet been
elucidated. This study sought to quantify the impact of TEVAR and
stent-graft oversizing on LAD in an ex-vivo porcine model.
METHODS Twenty fresh thoracic porcine aortas were harvested and
connected to a ﬂow pump at body temperature. The anterior side of
each aorta was marked every 5 cm from the left subclavian artery till
the celiac trunk. LAD measurements were conducted through high-
deﬁnition imaging and custom developed software at ﬁve different
pressure levels (100, 120, 140, 160 and 180 mmHg), before and after
TEVAR with a 150 mm long stent-graft. Three groups of oversizing
were created (0-9%, 10-19%, and 20-29%). Uniaxial tensile testing was
conducted after the experiment to evaluate the elastic properties of
the porcine aortas in the proximal, central and distal zones, from both
circumferential and longitudinal fragments.
RESULTS After TEVAR, LAD decreased in the stented segments (11.9%
vs. 5.6%, p<0.001) and in the total aorta (11.4% vs. 7.0%, p<0.001,
Figure 1). The positive linear correlation between LAD and pressure
was reduced at 120 mmHg in the stented segments (2.0% vs. 0.9%,
p<0.001) and in the total aorta (2.0% vs. 1.4%, p¼0.002), and
remained signiﬁcant for all higher pressures (Figure 1). Stent-graft
oversizing did not affect the level of LAD reduction (p¼0.797).
Tensile testing conﬁrmed homogeneity of aortic biomechanical
responses with a mean peak stress to rupture of 1.40.4 MPa and a
coefﬁcient of variation of 0.3. Moreover, mean peak stress was
higher for the circumferential than for the longitudinal fragments in
all three zones (2.30.4 MPa vs. 1.40.4 MPa, p¼0.01).CONCLUSIONS In this ex-vivo experimental model, LAD of the
healthy thoracic aorta decreased after TEVAR. Such longitudinal
stiffening may impact cardiovascular function and increase the risk of
cardiovascular disease and TEVAR-related complications. This study
may serve as a base for future investigation on the impact of thoracic
aortic stent-grafts and the cardiovascular system, and might
contribute to future stent-graft design.
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